

Specimen Collected: 13-Jun-23 05:51**LG11/CASPR2 Abs IgG CBA w/Rflx, Ser** | Received: 13-Jun-23 06:05 Report/Verified: 13-Jun-23 06:24

Procedure	Result	Units	Reference Interval
CASPR2 Ab IgG CBA-IFA Screen, Serum	Detected * t1 i1		[<1:10]
LG11 Ab IgG CBA-IFA Screen, Serum	Detected * t2 i2		[<1:10]

CASPR2 Ab IgG Titer by CBA-IFA, Ser | Received: 13-Jun-23 06:05 Report/Verified: 13-Jun-23 06:24

Procedure	Result	Units	Reference Interval
CASPR2 Ab IgG CBA-IFA Titer, Serum	1:80 * i3		[<1:10]

LGL1 Ab IgG Titer by CBA-IFA, Ser | Received: 13-Jun-23 06:05 Report/Verified: 13-Jun-23 06:24

Procedure	Result	Units	Reference Interval
LG11 Ab IgG CBA-IFA Titer, Serum	1:320 * i4		[<1:10]

Interpretive Text

t1: 13-Jun-23 05:51 (CASPR2 Ab IgG CBA-IFA Screen, Serum)
CASPR2 Antibody, IgG is detected. Titer results to follow.

t2: 13-Jun-23 05:51 (LG11 Ab IgG CBA-IFA Screen, Serum)
LG11 Antibody, IgG is detected. Titer results to follow.

Test Information

i1: CASPR2 Ab IgG CBA-IFA Screen, Serum
INTERPRETIVE INFORMATION: CASPR2 Ab IgG by IFA, Serum

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CASPR2 transfected cell lines for the detection and semiquantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: LG11 Ab IgG CBA-IFA Screen, Serum
INTERPRETIVE INFORMATION: LG11 Ab IgG Screen by IFA, Serum

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-164-900034**Report Request ID:** 17763705**Printed:** 19-Jun-23 11:30

Page 1 of 2

Test Information

i2: LGI1 Ab IgG CBA-IFA Screen, Serum
Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semiquantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: CASPR2 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: CASPR2 Ab Titer IgG by IFA,
Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: LGI1 Ab IgG CBA-IFA Titer, Serum
INTERPRETIVE INFORMATION: LGI1 Ab Titer IgG by IFA,
Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-164-900034

Report Request ID: 17763705

Printed: 19-Jun-23 11:30

Page 2 of 2